| Parent Drug Name | Name of Impurity | Catalogue No. | |
|---|---|---|---|
| Cangrelor | Cangrelor 6-Amino Triol Impurity | VE008675 | View CAS 163706-51-2 |
| Cangrelor | Cangrelor Phosphate Impurity | VE008672 | View CAS 847460-53-1 |
| Cangrelor | Des Ribose Cangrelor Impurity | VE008670 | View CAS 1830294-25-1 |
| Cangrelor | N-[2-(methylthio)ethyl]-2-[(3, 3, 3-trifluoropropyl)thio]-5’-adenylic Acid (9CI) | VE008673 | View CAS 163706-58-9 |
| Cangrelor | 2-Thioadenosine | VE008674 | View CAS 43157-50-2 |
| Catalogue No. | VE008675 |
| CAS No. | 163706-51-2 |
| Molecular Formula | C13H16F3N5O4S |
| Molecular Weight | 395.36 g/mol |
| Parent drug | Cangrelor |
| IUPAC Name | 2-[(3, 3, 3-Trifluoropropyl)thio]adenosine |
| Synonyms | N/A |
| References | Feng, Kent Y., and Kenneth W. Mahaffey. “Cangrelor in Clinical Use.” Future Cardiology, vol. 16, no. 2, Mar. 2020, pp. 89–102, https://doi.org/10.2217/fca-2019-0095. |
| Status | In-stock |
| ListName | Cangrelor 6-Amino Triol Impurity |
| Exclusively Supplied by Veeprho | Exclusively Supplied by Veeprho |
"*" indicates required fields
